ncRNA basic information ncRNA ID: MI0000238/MI0000279 ncRNA Database: miRBase ncRNA Name: miR-196a ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: HOXA5 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: The aim of this study was to evaluate the effects of miRNA-196a on the sensitivity of NSCLC cells to cisplatin in vitro and in vivo. RT-qPCR was used to detect miRNA-196a expression. Synthesized locked nucleic acid (LNA)-anti-miRNA-196a oligonucleotide was transiently transfected into the SPC-A-1 and A549 lung cancer cells to examine the effects of miRNA-196a on the growth of and colony formation inthe cisplatin-treated cells. The effects of miRNA-196a on the sensitivity of SPC-A-1 cells to cisplatin in vivo were determined using BALB/c nude mice. The expression of miRNA-196a was significantly higher in both the lung cancer tissues and cell lines. The LNA-based knockdown of miRNA-196a significantly inhibited SPC-A-1 and A549 cell growth and induced apoptosis. Moreover, the downregulation of miRNA-196a sensitized the SPC-A-1 and A549 NSCLC cells to cisplatin in vitro and in vivo, by inducing apoptosis. Drug Response: sensitive

Cancer basic information Cancer: lung non-small cell carcinoma Tissue/Cell: tissue and cell line (A549, SPC-A-1, NCI-H1650, NCI-H1299,SK-MES-1)

Other information Title: Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment. Journal: Int J Mol Med Published: 2016 PubMed ID: 26936095